SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Director Option Grant

24 Nov 2025 12:28

RNS Number : 7639I
Tristel PLC
24 November 2025
 

TRISTEL plc

("Tristel" or the "Company")

 

Director Option Grant

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that on 24 November 2025 it granted a total of 181,972 new share options (the "Options") over ordinary shares of 1 pence each ("Ordinary Shares") under the Long Term Incentive Plan ("LTIP") in the Company, to two directors as follows:

 

Director's name

Position

Number of Options granted

Aggregate number of options post grant

Current total beneficial holding of Ordinary Shares

Current holding as a % of Issued share capital

Matt Sassone

CEO

106,479

183,483

3,500

0.01%

Anna Wasyl

CFO

75,493

75,493

0

0%

 

Terms of the new LTIP

The performance targets for the LTIP awards, which have been adjusted to reflect the impact of the tax rate and the investments required to stimulate growth, will be 50% based on earning per share (EPS) targets and 50% based on relative total shareholder return (TSR) versus the constituents of the AIM 100 as at the grant of the awards as follows:

 

50% of Initial awards

50% of Initial awards

 

EPS FY 27/28

% of EPS Part that Vests

Relative TSR measured over 3 years from grant

% of TSR Part that Vests

Less than 19p

0%

Below median

0%

Between 19p and 23p

Pro-rata 25% to 100%

Between median and upper quartile

Pro-rata 25% to 100%

23p or better

100%

Upper quartile or above

100%

 

This announcement was deemed by the company to contain inside information as stipulated under the Market Abuse Regulations (EU) no. 596/2014 as they form part of UK domestic law by virtue of the European Union (withdrawal) Act 2018. With the publication of this announcement, this information is now considered to be in the public domain.

 

 

For further information please contact:

Tristel plc

Via Walbrook PR

Matt Sassone, Chief Executive Officer

www.investors.tristel.com

Anna Wasyl, Chief Financial Officer

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus / Lianne Applegarth / Anna Dunphy 

Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

Cavendish Capital Markets Ltd

Tel: 020 7220 0500

Geoff Nash / Callum Davidson / Trisyia Jamaludin (Corporate Finance)

Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

 

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 20 subsidiaries selling into 40+ countries. The Company targets double digit revenue growth annually and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit: https://tristel.com

 

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014 which forms part of UK Law by virtue of the European Union (Withdrawal) Act 2018.

 

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Matthew Sassone

2. 

Reason for the Notification

a)

Position/status

CEO

b)

Initial notification/Amendment

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Tristel plc

b)

LEI

2138009DZ4LH9CZGF662

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 1p each

Identification code

GB00B07RVT99 

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

1 pence, 106,479 shares

 

 

d)

Aggregated information:

· Aggregated volume

· Price

See above

 

e)

Date of the transaction

24 November 2025

f)

Place of the transaction

Outside of a trading venue

 

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Anna Wasyl

2. 

Reason for the Notification

a)

Position/status

CFO

b)

Initial notification/Amendment

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Tristel plc

b)

LEI

2138009DZ4LH9CZGF662

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 1p each

Identification code

GB00B07RVT99 

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

1 pence, 75,493 shares

 

 

d)

Aggregated information:

· Aggregated volume

· Price

See above

 

e)

Date of the transaction

24 November 2025

f)

Place of the transaction

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHPKQBBBBDDBDB
Date   Source Headline
10th Jun 20267:00 amRNSExercise of Share Options & Total Voting Rights
13th May 202610:10 amRNSExercise of Share Options and Total Voting Rights
5th May 20267:00 amRNSExercise of Share Options and Total Voting Rights
20th Apr 20262:28 pmRNSHolding(s) in Company
20th Apr 20268:20 amRNSHolding(s) in Company
23rd Mar 20267:00 amRNSDirector/PDMR Shareholding
18th Mar 20267:00 amRNS-RConference attendance at ShareSoc Leeds
17th Mar 20265:13 pmRNSHolding(s) in Company
3rd Mar 20264:04 pmRNSPCA Dealing
2nd Mar 20267:00 amRNSHalf-year Financial Report
12th Feb 20267:00 amRNSExercise of Share Options and Total Voting Rights
6th Feb 202611:56 amRNSExercise of Share Options and Total Voting Rights
6th Feb 20267:00 amRNSNotice of Results
22nd Jan 20267:00 amRNSPositive H1 Trading Update & Directorate Change
8th Jan 20263:10 pmRNSExercise of Share Options and Total Voting Rights
12th Dec 202510:37 amRNSDirector/PDMR Shareholding
12th Dec 20259:19 amRNSExercise of Share Options and Total Voting Rights
11th Dec 202511:54 amRNSResult of AGM
11th Dec 20257:00 amRNSAGM Statement
24th Nov 202512:28 pmRNSDirector Option Grant
24th Nov 20257:00 amRNSUpdated US guidelines for high level disinfection
18th Nov 20257:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
12th Nov 202511:33 amRNSHolding(s) in Company
31st Oct 20254:11 pmRNSHolding(s) in Company
31st Oct 20252:12 pmRNSHolding(s) in Company
22nd Oct 20254:56 pmRNSHolding(s) in Company
16th Oct 20254:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 202512:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 20257:00 amRNSFinal Results
9th Oct 202510:06 amRNSExercise of Share Options and Total Voting Rights
25th Sep 20257:00 amRNSVISICLEAN Product Launch
16th Sep 20257:00 amRNSNotice of Preliminary Results
11th Sep 20257:00 amRNSExercise of Share Options and Total Voting Rights
1st Sep 20257:00 amRNSConfirmation of CFO Appointment
21st Aug 20253:56 pmRNSHolding(s) in Company
18th Aug 202512:15 pmRNSExercise of Share Options and Total Voting Rights
6th Aug 20254:05 pmRNS-RCapital Markets Day video update
29th Jul 20257:00 amRNSTrading update
24th Jul 20257:00 amRNSConfirmation of Investor presentations
17th Jul 20257:00 amRNSAppointment of Chief Financial Officer
4th Jul 20251:02 pmRNSHolding(s) in Company
26th Jun 20257:00 amRNS-RAPIC25 Annual Conference attendance
2nd Jun 20257:00 amRNSInvestor Presentations & Notice of Trading Update
30th May 20257:00 amRNSHolding(s) in Company
28th May 20257:00 amRNS-RConference attendance at Mello2025 Investor event
16th May 20257:00 amRNSExercise of Share Options and Total Voting Rights
15th May 20257:00 amRNSCFO succession planning
12th May 20257:00 amRNSFDA clearance for Tristel OPH
10th Apr 20257:00 amRNSAdditional info. submitted to FDA for Tristel OPH
9th Apr 20257:00 amRNSPublication of Poster by Mayo Clinic & US update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.